Kraus S, Dierks A, Rasche L, Kertels O, Kircher M, Schirbel A, Zovko J, Steinbrunn T, Tibes R, Wester HJ, Buck AK, Einsele H, Kortum KM, Rosenwald A, Lapa C (2022)
Publication Type: Journal article
Publication year: 2022
Book Volume: 63
Pages Range: 96-99
Journal Issue: 1
DOI: 10.2967/jnumed.121.262206
C-X-C motif chemokine receptor 4 (CXCR4) is an attractive target for cancer diagnosis and treatment, as it is overexpressed in many solid and hematologic malignancies. This study investigated the feasibility of CXCR4-directed imaging with PET/CT using 68Ga-pentixafor to visualize and quantify disease involvement in myeloproliferative neoplasms (MPNs). Methods: Twelve patients with MPNs (4 with primary myelofibrosis, 6 with essential thrombocythemia, and 2 with polycythemia vera) and 5 controls underwent 68Ga-pentixafor PET/CT. Imaging findings were compared with immunohistochemical stainings, laboratory data, and splenic volume. Results: 68Ga-pentixafor PET/ CT was visually positive in 12 of 12 patients, and CXCR4 target specificity could be confirmed by immunohistochemical staining. A significantly higher tracer uptake could be detected in the bone marrow of MPN patients (SUVmean, 6.45±2.34 vs. 4.44±1.24). Dynamic changes in CXCR4 expression determined by 68Ga-pentixafor PET/ CT corresponded with treatment response. Conclusion: 68Ga-pentixafor PET/CT represents a novel diagnostic tool to noninvasively detect and quantify the extent of disease involvement inMPNs. COPYRIGHT
APA:
Kraus, S., Dierks, A., Rasche, L., Kertels, O., Kircher, M., Schirbel, A.,... Lapa, C. (2022). 68Ga-Pentixafor PET/CT for Detection of Chemokine Receptor CXCR4 Expression in Myeloproliferative Neoplasms. Journal of Nuclear Medicine, 63(1), 96-99. https://doi.org/10.2967/jnumed.121.262206
MLA:
Kraus, Sabrina, et al. "68Ga-Pentixafor PET/CT for Detection of Chemokine Receptor CXCR4 Expression in Myeloproliferative Neoplasms." Journal of Nuclear Medicine 63.1 (2022): 96-99.
BibTeX: Download